foslevodopa/foscarbidopa vs Levodopa (Inbrija)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Parkinson's Disease

Shared mechanism: dopamine precursor · full Parkinson's Disease pipeline

foslevodopa/foscarbidopa · Vyalev

Marketed by AbbVie

Approved in Parkinson's Diseasesmall molecule
Reliable signal

NCT04380142 · Phase 3 · completed

The trial randomized 145 participants to active treatment or an active comparator, with participants, clinicians, investigators, and outcome assessors quadruple-blinded. The primary clinical endpoint was met: least-squares mean improvement in “On” time was 2.72 hours with ABBV-951 versus 0.97 hours with oral carbidopa/levodopa, a difference of 1.75 hours (95% CI 0.46–3.05; p=0.0083).

Reported efficacy

Change From Baseline to Week 12 of the Double-Blind Treatment Period in Average Daily Normalized "On" Time Without Troublesome Dyskinesia (Baseline (Week 0) up to Week 12 of the double-blind treatment period): Change From Baseline to Week 12 of the Double-Blind Treatment Period in Average Daily Normalized "On" Time Without Troublesome Dyskinesia (Baseline (Week 0) up to Week 12 of the double-blind treatment period): ABBV-951 + Placebo for LD/CD 2.72 hours (Standard Error 0.52) vs LD/CD + Placebo for ABBV-951 0.97 hours (Standard Error 0.5) (met)

Result source: NCT04380142

Levodopa (Inbrija)

Marketed by Merz Therapeutics and partners

Approved in Parkinson's Diseasesmall molecule
Partial signal

NCT02240030 · Phase 3 · completed

This randomized, double-blind, placebo-controlled phase 3 trial assigned 351 participants to CVT-301 60 mg, CVT-301 84 mg or placebo. Its clinical primary endpoint, the change in UPDRS motor score from predose to 30 minutes post-dose at week 12 for 84 mg versus placebo, was met: -9.83 versus -5.91, a difference of -3.92 points (95% CI -6.84 to -1.00; p=0.0088), as reported in the peer-reviewed publication.

Reported efficacy

Unified Parkinson's Disease Rating Scale (UPDRS) Part III (30 minutes post-dose at week 12): UPDRS motor score change, predose to 30 min post-dose at week 12: CVT-301 84 mg -9.83 vs placebo -5.91; difference -3.92 (95% CI -6.84 to -1.00), p=0.0088 (LeWitt et al., Lancet Neurol 2019) (met)

Result source: NCT02240030

Results for Parkinson's Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointfoslevodopa/​foscarbidopaLevodopa (Inbrija)
OFF time, change-2.8 vs -1.0vs LD/CDwk 12 · n 47NCT04380142—Not reported
ON time without troublesome dyskinesia, change2.7 vs 1.0vs LD/CDwk 12 · n 47NCT04380142—Not reported
UPDRS Part III, change—Not posted · NCT04379050-9.8 vs -5.9−3.9 vs placebowk 12 · n 114NCT02240030
4 other results
  • -8.5 vs -6.5 wk 12 · n 113 · Phase 3 · secondary NCT02240030
  • -9.0 vs -6.5 wk 12 · n 114 · Phase 3 · secondary NCT02240030
  • -5.2 vs -4.2 wk 12 · n 113 · Phase 3 · secondary NCT02240030
  • -6.5 vs -4.2 wk 12 · n 114 · Phase 3 · secondary NCT02240030
MDS-UPDRS Part II, change-2.6 vs -1.1vs LD/CDwk 12 · n 46NCT04380142—Not reported

OFF time, change

foslevodopa/​foscarbidopa
-2.8 vs -1.0vs LD/CDwk 12 · n 47NCT04380142
Levodopa (Inbrija)
—Not reported

ON time without troublesome dyskinesia, change

foslevodopa/​foscarbidopa
2.7 vs 1.0vs LD/CDwk 12 · n 47NCT04380142
Levodopa (Inbrija)
—Not reported

UPDRS Part III, change

foslevodopa/​foscarbidopa
—Not posted · NCT04379050
Levodopa (Inbrija)
-9.8 vs -5.9−3.9 vs placebowk 12 · n 114NCT02240030
4 other results
  • -8.5 vs -6.5 wk 12 · n 113 · Phase 3 · secondary NCT02240030
  • -9.0 vs -6.5 wk 12 · n 114 · Phase 3 · secondary NCT02240030
  • -5.2 vs -4.2 wk 12 · n 113 · Phase 3 · secondary NCT02240030
  • -6.5 vs -4.2 wk 12 · n 114 · Phase 3 · secondary NCT02240030

MDS-UPDRS Part II, change

foslevodopa/​foscarbidopa
-2.6 vs -1.1vs LD/CDwk 12 · n 46NCT04380142
Levodopa (Inbrija)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. foslevodopa/foscarbidopa: 4 of 4 rows · Levodopa (Inbrija): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricfoslevodopa/​foscarbidopaLevodopa (Inbrija)
Dropout rate
—
NCT04380142 · Phase 3 · Parkinson's Disease · phase 3
show 3 more results
—ABBV-951 All Participants
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
42.5%high dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
35.9%low dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
14.9%CVT-301 High Dosea
NCT02240030 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 4 more results
15%CVT-301 Low Dose
NCT02240030 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
28.7%HIgh Dose
NCT02242487 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
38.5%Low Dose
NCT02242487 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
2.5%
NCT02352363 · Phase 3 · monotherapy
Discontinued due to AEs
—
NCT04380142 · Phase 3 · Parkinson's Disease · phase 3
show 3 more results
—ABBV-951 All Participants
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
22.1%high dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
17.6%low dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
—CVT-301 High Dosea
NCT02240030 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 4 more results
—CVT-301 Low Dose
NCT02240030 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
9.1%HIgh Dose
NCT02242487 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
8.1%Low Dose
NCT02242487 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
—
NCT02352363 · Phase 3 · monotherapy
Serious AEs
8.1%
NCT04380142 · Phase 3 · Parkinson's Disease · phase 3
show 3 more results
25.8%ABBV-951 All Participants
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
27.4%high dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
24.4%low dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
1.8%CVT-301 High Dosea
NCT02240030 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 4 more results
5.3%CVT-301 Low Dose
NCT02240030 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
8.2%HIgh Dose
NCT02242487 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
14.4%Low Dose
NCT02242487 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
15.5%
NCT02352363 · Phase 3 · monotherapy
Most frequent reported AEs
infusion site erythema 27%
infusion site pain 25.7%
infusion site cellulitis 17.6%
NCT04380142 · Phase 3 · Parkinson's Disease · phase 3
show 3 more results
infusion site erythema 52%
infusion site nodule 28.7%
infusion site oedema 19.3%
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
high dose
infusion site erythema 55.8%
infusion site nodule 30.1%
infusion site oedema 24.8%
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
low dose
infusion site erythema 48.9%
infusion site nodule 27.5%
infusion site cellulitis 19.1%
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
a
cough 14.9% (placebo 1.8%)
upper respiratory tract 6.1% (placebo 2.7%)
nausea 5.3% (placebo 2.7%)
NCT02240030 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 4 more results
cough 15% (placebo 1.8%)
throat irritation 7.1% (placebo 0%)
dyskinesia 4.4% (placebo 0%)
NCT02240030 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
HIgh Dose
cough 14.5%
fall 10.7%
upper respiratory tract infection 7.5%
NCT02242487 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
Low Dose
cough 16.3%
fall 15.7%
upper respiratory tract infection 6.5%
NCT02242487 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
cough 13.3%
fall 8.1%
nasopharyngitis 6.6%
NCT02352363 · Phase 3 · monotherapy

Notes

  1. aPopulation comparability has not been reviewed for 1 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

foslevodopa/foscarbidopa

On" Time Without Troublesome Dyskinesia 2.72 vs 0.97 LD/CD hours @ 12wk
absolute change · hours
NCT04380142 · Phase 3 · Parkinson's Disease · phase 3
OFF Time -2.75 vs -0.96 LD/CD hours @ 12wk
absolute change · hours
NCT04380142 · Phase 3 · Parkinson's Disease · phase 3
MDS-UPDRS Part II -2.65 vs -1.06 LD/CD score @ 12wk
absolute change · score
NCT04380142 · Phase 3 · Parkinson's Disease · phase 3
Early Morning "Off 17% (n=47) vs 63.3% (n=60) LD/CD @ 12wk
responder rate · % of participants
NCT04380142 · Phase 3 · Parkinson's Disease · phase 3
ON Time Without Dyskinesia 3.13 vs 1.32 LD/CD hours @ 12wk
absolute change · hours
NCT04380142 · Phase 3 · Parkinson's Disease · phase 3
PDSS-2 Total -7.92 vs -2.52 LD/CD score @ 12wk
absolute change · score
NCT04380142 · Phase 3 · Parkinson's Disease · phase 3
PDQ-39 Summary Index -6.38 vs -2.28 LD/CD score @ 12wk
absolute change · score
NCT04380142 · Phase 3 · Parkinson's Disease · phase 3
EQ-5D-5L Summary Index 0.051 vs 0.002 LD/CD score @ 12wk
absolute change · score
NCT04380142 · Phase 3 · Parkinson's Disease · phase 3
OFF Time -2.04 hours @ 1wklow dose
absolute change · hours
No placebo or comparator arm
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 17 more results
-1.84 hours @ 1wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-1.95 hours @ 1wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.43 hours @ 6wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.36 hours @ 6wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.4 hours @ 6wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.5 hours @ 13wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.34 hours @ 13wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.43 hours @ 13wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-3.31 hours @ 26wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-3.38 hours @ 26wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-3.35 hours @ 26wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-3.25 hours @ 39wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-3.52 hours @ 39wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-3.37 hours @ 39wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-3.43 hours @ 52wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-3.59 hours @ 52wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-3.51 hours @ 52wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
Daily on Time With Troublesome Dyskinesia 0 hours @ 1wklow dose
absolute change · hours
No placebo or comparator arm
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 17 more results
0.11 hours @ 1wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
0.05 hours @ 1wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.56 hours @ 6wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.23 hours @ 6wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.41 hours @ 6wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.6 hours @ 13wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.38 hours @ 13wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.5 hours @ 13wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.61 hours @ 26wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.27 hours @ 26wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.45 hours @ 26wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.49 hours @ 39wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.17 hours @ 39wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.35 hours @ 39wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.64 hours @ 52wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
0.17 hours @ 52wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.27 hours @ 52wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
Daily on Time Without Troublesome Dyskinesia 2.04 hours @ 1wklow dose
absolute change · hours
No placebo or comparator arm
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 17 more results
1.74 hours @ 1wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
1.9 hours @ 1wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
2.99 hours @ 6wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
2.6 hours @ 6wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
2.81 hours @ 6wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
3.1 hours @ 13wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
2.72 hours @ 13wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
2.93 hours @ 13wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
3.92 hours @ 26wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
3.65 hours @ 26wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
3.79 hours @ 26wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
3.74 hours @ 39wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
3.69 hours @ 39wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
3.71 hours @ 39wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
4.08 hours @ 52wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
3.43 hours @ 52wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
3.77 hours @ 52wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
MDS-UPDRS Part I -2.6 score @ 0.29wklow dose
absolute change · score
No placebo or comparator arm
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 29 more results
-1.8 score @ 0.29wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.3 score @ 0.29wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.6 score @ 1wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-3.3 score @ 1wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.9 score @ 1wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.5 score @ 2wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.1 score @ 2wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.3 score @ 2wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.3 score @ 3wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.9 score @ 3wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.6 score @ 3wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-1.7 score @ 4wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-3 score @ 4wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-2.3 score @ 4wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-1.1 score @ 6wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-1.7 score @ 6wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-1.4 score @ 6wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-1.8 score @ 13wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-1.7 score @ 13wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-1.7 score @ 13wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-1.1 score @ 26wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.7 score @ 26wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.9 score @ 26wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.7 score @ 39wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
0.1 score @ 39wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.4 score @ 39wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.5 score @ 52wklow dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-1.3 score @ 52wkhigh dose
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.9 score @ 52wk
NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3

+ 6 further endpoints in the CSV export.

Levodopa (Inbrija)

UPDRS Part III -9.83 vs -5.91 placebo score @ 12wk
absolute change · score
NCT02240030 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 4 more results
-8.47 vs -6.49 placebo score @ 12wk
NCT02240030 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-9.04 vs -6.49 placebo score @ 12wk
NCT02240030 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-5.16 vs -4.18 placebo score @ 12wk
NCT02240030 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-6.45 vs -4.18 placebo score @ 12wk
NCT02240030 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
OFF to ON Resolution 60 Min 48.7% (n=113) vs 31.3% (n=112) placebo @ 12wk
event count · % of participants
NCT02240030 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 · converted to % from 55 Participants as posted
show 1 more result
49.1% (n=114) vs 31.3% (n=112) placebo @ 12wk*
NCT02240030 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 · converted to % from 56 Participants as posted
PGIC Improvement 54% (n=113) vs 40.2% (n=112) placebo @ 12wk
event count · % of participants
NCT02240030 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 · converted to % from 61 Participants as posted
show 1 more result
61.4% (n=114) vs 40.2% (n=112) placebo @ 12wk*
NCT02240030 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 · converted to % from 70 Participants as posted
OFF to ON 60 Min 54.2% (n=144) @ 52wkDL1
responder rate · % of participants
No placebo or comparator arm
NCT02242487 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 · converted to % from 78 Participants as posted
show 1 more result
60.1% (n=153) @ 52wk*DL2
NCT02242487 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 · converted to % from 92 Participants as posted
OFF Time -0.33 hours @ 4wkDL1
absolute change · hours
No placebo or comparator arm
TV2 (Week 4)
NCT02242487 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 1 more result
-0.55 hours @ 4wkDL2
TV2 (Week 4)
NCT02242487 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
OFF Time -0.23 hours @ 12wkDL1
absolute change · hours
No placebo or comparator arm
TV3 (Week 12)
NCT02242487 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 1 more result
-0.38 hours @ 12wkDL2
TV3 (Week 12)
NCT02242487 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
OFF Time -0.65 hours @ 24wkDL1
absolute change · hours
No placebo or comparator arm
TV4 (Week 24)
NCT02242487 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 1 more result
-0.73 hours @ 24wkDL2
TV4 (Week 24)
NCT02242487 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
OFF Time -0.49 hours @ 36wkDL1
absolute change · hours
No placebo or comparator arm
TV5 (Week 36)
NCT02242487 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 1 more result
-0.92 hours @ 36wkDL2
TV5 (Week 36)
NCT02242487 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
OFF Time -0.7 hours @ 52wkDL1
absolute change · hours
No placebo or comparator arm
TV6 (Week 52)
NCT02242487 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 1 more result
-0.88 hours @ 52wkDL2
TV6 (Week 52)
NCT02242487 · Phase 3 · monotherapy · Parkinson's Disease · phase 3

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: foslevodopa/foscarbidopa's landscape · Levodopa (Inbrija)'s landscape